专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5700823A Treatment of platelet derived growth factor related disorders such as cancers 失效
标题翻译：治疗血小板衍生生长因子相关疾病如癌症
公开(公告)号：US5700823A
公开(公告)日：1997-12-23
申请号：US179570
申请日：1994-01-07
申请人： Klaus Peter Hirth , Donna Pruess Schwartz , Elaina Mann , Laura Kay Shawver , Gyorgy Keri , Istvan Szekely , Tamas Bajor , Janis Haimichael , Laszlo Orfi , Alex Levitzki , Aviv Gazit , Axel Ullrich , Reiner Lammers
发明人： Klaus Peter Hirth , Donna Pruess Schwartz , Elaina Mann , Laura Kay Shawver , Gyorgy Keri , Istvan Szekely , Tamas Bajor , Janis Haimichael , Laszlo Orfi , Alex Levitzki , Aviv Gazit , Axel Ullrich , Reiner Lammers
IPC分类号： A61K9/00 , A61K31/165 , A61K31/167 , A61K31/275 , A61K31/277 , A61K31/38 , A61K31/40 , A61K31/415 , A61K31/42 , A61K31/421 , A61K31/425 , A61K31/44 , A61K31/47 , A61K31/495 , A61K31/505 , A61K31/535 , A61K45/06 , A61K47/10 , A61K47/26 , C07C255/23 , C07D231/38 , C07D239/91 , C07D241/38 , C07D241/42 , C07D487/04 , C07D498/04 , G01N33/50 , A61K31/175
CPC分类号： C07D231/38 , A61K31/165 , A61K31/167 , A61K31/275 , A61K31/277 , A61K31/38 , A61K31/40 , A61K31/415 , A61K31/42 , A61K31/421 , A61K31/425 , A61K31/44 , A61K31/47 , A61K31/495 , A61K31/505 , A61K31/535 , A61K45/06 , A61K47/10 , A61K47/26 , A61K9/0019 , C07C255/23 , C07D239/91 , C07D241/38 , C07D241/42 , C07D487/04 , G01N33/5011 , Y10S977/904 , Y10S977/911 , Y10S977/912 , Y10S977/915
摘要： Method for treating a patient inflicted with a cell proliferation disorder, such as a cancer, characterized by inappropriate PDGF-R activity. The method involves the step of administering to the patient a therapeutically effective amount of a composition described in application.
摘要翻译：用于治疗患有细胞增殖病症（例如癌症）的患者的方法，其特征在于不适当的PDGF-R活性。该方法包括向患者施用治疗有效量的应用中描述的组合物的步骤。

2. 发明授权

US5700822A Treatment of platelet derived growth factor related disorders such as cancers 失效
标题翻译：治疗血小板衍生生长因子相关疾病如癌症
公开(公告)号：US5700822A
公开(公告)日：1997-12-23
申请号：US457047
申请日：1995-06-01
申请人： Klaus Peter Hirth , Donna Pruess Schwartz , Elaina Mann , Laura Kay Shawver , Gyorgi Keri , Istvan Szekely , Tamas Bajor , Janis Haimichael , Laszlo Orfi , Alex Levitzki , Aviv Gazit , Axel Ullrich , Reiner Lammers , Fairooz F. Kabbinavar , Dennis Slamon , Peng Cho Tang
发明人： Klaus Peter Hirth , Donna Pruess Schwartz , Elaina Mann , Laura Kay Shawver , Gyorgi Keri , Istvan Szekely , Tamas Bajor , Janis Haimichael , Laszlo Orfi , Alex Levitzki , Aviv Gazit , Axel Ullrich , Reiner Lammers , Fairooz F. Kabbinavar , Dennis Slamon , Peng Cho Tang
IPC分类号： A61K9/00 , A61K31/165 , A61K31/167 , A61K31/275 , A61K31/277 , A61K31/38 , A61K31/40 , A61K31/415 , A61K31/42 , A61K31/421 , A61K31/425 , A61K31/44 , A61K31/47 , A61K31/495 , A61K31/505 , A61K31/535 , A61K45/06 , A61K47/10 , A61K47/26 , C07C255/23 , C07D231/38 , C07D239/91 , C07D241/38 , C07D241/42 , C07D487/04 , C07D498/04 , G01N33/50
CPC分类号： C07D231/38 , A61K31/165 , A61K31/167 , A61K31/275 , A61K31/277 , A61K31/38 , A61K31/40 , A61K31/415 , A61K31/42 , A61K31/421 , A61K31/425 , A61K31/44 , A61K31/47 , A61K31/495 , A61K31/505 , A61K31/535 , A61K45/06 , A61K47/10 , A61K47/26 , A61K9/0019 , C07C255/23 , C07D239/91 , C07D241/38 , C07D241/42 , C07D487/04 , G01N33/5011 , Y10S977/904 , Y10S977/911 , Y10S977/912 , Y10S977/915
摘要： The present invention concerns compounds which can inhibit platelet derived growth factor receptor (PDGF-R) activity, preferably such compounds also inhibit the activity other members of the PDGF-R super family and are selective for members of the PDGF-R super family. The PDGF-R super family includes PDGF-R and PDGF-R related kinases Flt, and KDR. The featured compounds are active on cell cultures to reduce the activity of the PDGF-R and preferably one or more PDGF-R related kinases. An example of a featured compound, A10 (see FIG. 1a), and its ability to inhibit growth of tumor cells in vivo is described below. Using the present application as guide other compounds able to inhibit PDGF-R and preferably Flt and/or KDR can be obtained. Such compounds are preferably used to treat patients suffering from cell proliferative disorders characterized by inappropriate PDGF-R activity.
摘要翻译：本发明涉及可以抑制血小板衍生生长因子受体（PDGF-R）活性的化合物，优选地，这些化合物也抑制PDGF-R超家族的其他成员的活性，并且对PDGF-R超家族的成员是选择性的。 PDGF-R超家族包括PDGF-R和PDGF-R相关的激酶Flt和KDR。特征化合物在细胞培养物中是有活性的，以降低PDGF-R，优选一种或多种PDGF-R相关激酶的活性。以下描述特征化合物A10（参见图1a）及其抑制体内肿瘤细胞生长的能力的实例。使用本申请作为指导，可以获得能够抑制PDGF-R，优选Flt和/或KDR的其它化合物。这些化合物优选用于治疗患有以不适当的PDGF-R活性为特征的细胞增殖性疾病的患者。

3. 发明授权

US5990141A Treatment of platelet derived growth factor related disorders such as cancers 失效
标题翻译：治疗血小板衍生生长因子相关疾病如癌症
公开(公告)号：US5990141A
公开(公告)日：1999-11-23
申请号：US370574
申请日：1995-01-06
申请人： Klaus Peter Hirth , Donna Pruess Schwartz , Elaina Mann , Laura Kay Shawver , Gyorgi Keri , Istvan Szekely , Tamas Bajor , Janis Haimichael , Laszlo Orfi , Alex Levitzki , Aviv Gazit , Axel Ullrich , Reiner Lammers , Fairooz F. Kabbinavar , Dennis Slamon , Peng Cho Tang
发明人： Klaus Peter Hirth , Donna Pruess Schwartz , Elaina Mann , Laura Kay Shawver , Gyorgi Keri , Istvan Szekely , Tamas Bajor , Janis Haimichael , Laszlo Orfi , Alex Levitzki , Aviv Gazit , Axel Ullrich , Reiner Lammers , Fairooz F. Kabbinavar , Dennis Slamon , Peng Cho Tang
IPC分类号： A61K9/00 , A61K31/165 , A61K31/167 , A61K31/275 , A61K31/277 , A61K31/38 , A61K31/40 , A61K31/415 , A61K31/42 , A61K31/421 , A61K31/425 , A61K31/44 , A61K31/47 , A61K31/495 , A61K31/505 , A61K31/535 , A61K45/06 , A61K47/10 , A61K47/26 , C07C255/23 , C07D231/38 , C07D239/91 , C07D241/38 , C07D241/42 , C07D487/04 , C07D498/04 , G01N33/50
CPC分类号： C07D231/38 , A61K31/165 , A61K31/167 , A61K31/275 , A61K31/277 , A61K31/38 , A61K31/40 , A61K31/415 , A61K31/42 , A61K31/421 , A61K31/425 , A61K31/44 , A61K31/47 , A61K31/495 , A61K31/505 , A61K31/535 , A61K45/06 , A61K47/10 , A61K47/26 , A61K9/0019 , C07C255/23 , C07D239/91 , C07D241/38 , C07D241/42 , C07D487/04 , G01N33/5011 , Y10S977/904 , Y10S977/911 , Y10S977/912 , Y10S977/915
摘要： The present invention concerns compounds which can inhibit platelet derived growth factor receptor (PDGF-R) activity, preferably such compounds also inhibit the activity other members of the PDGF-R super family and are selective for members of the PDGF-R super family. The PDGF-R super family includes PDGF-R and PDGF-R related kinases Flt, and KDR. The featured compounds are active on cell cultures to reduce the activity of the PDGF-R and preferably one or more PDGF-R related kinases. An example of a featured compound, A10 (see FIG. 1a), and its ability to inhibit growth of tumor cells in vivo is described below. Using the present application as guide other compounds able to inhibit PDGF-R and preferably Flt and/or KDR can be obtained. Such compounds are preferably used to treat patients suffering from cell proliferative disorders characterized by inappropriate PDGF-R activity.
摘要翻译：本发明涉及可以抑制血小板衍生生长因子受体（PDGF-R）活性的化合物，优选地，这些化合物也抑制PDGF-R超家族的其他成员的活性，并且对PDGF-R超家族的成员是选择性的。 PDGF-R超家族包括PDGF-R和PDGF-R相关的激酶Flt和KDR。特征化合物在细胞培养物中是有活性的，以降低PDGF-R，优选一种或多种PDGF-R相关激酶的活性。下面描述特征化合物A10（参见图1a）及其抑制体内肿瘤细胞生长的能力的实例。使用本申请作为指导，可以获得能够抑制PDGF-R，优选Flt和/或KDR的其它化合物。这些化合物优选用于治疗患有以不适当的PDGF-R活性为特征的细胞增殖性疾病的患者。

4. 发明授权

US06331555B1 Treatment of platelet derived growth factor related disorders such as cancers 失效
标题翻译：治疗血小板衍生生长因子相关疾病如癌症
公开(公告)号：US06331555B1
公开(公告)日：2001-12-18
申请号：US09363237
申请日：1999-07-27
申请人： Klaus P. Hirth , Elaina Mann , Laura K. Shawyer , Axel Ullrich , Istvan Szekely , Tamas Bajor , Janis Haimichael , Laszlo Orfi , Alex Levitzki , Aviv Gazit , Peng Cho Tang , Reiner Lammers
发明人： Klaus P. Hirth , Elaina Mann , Laura K. Shawyer , Axel Ullrich , Istvan Szekely , Tamas Bajor , Janis Haimichael , Laszlo Orfi , Alex Levitzki , Aviv Gazit , Peng Cho Tang , Reiner Lammers
IPC分类号： A61K3142
CPC分类号： A61K31/135 , A61K31/12 , A61K31/13 , A61K31/415 , A61K31/42
摘要： The present invention concerns compounds which can inhibit platelet derived growth factor receptor (PDGF-R) activity, preferably such compounds also inhibit the activity other members of the PDGF-R super family and are selective for members of the PDGF-R super family. The PDGF-R super family includes PDGF-R and PDGF-R related kinases Flt, and KDR. The featured compounds are active on cell cultures to reduce the activity of the PDGF-R and preferably one or more PDGF-R related kinases. An example of a featured compound, A10 (see FIG. 1a), and its ability to inhibit growth of tumor cells in vivo is described below. Using the present application as guide other compounds able to inhibit PDGF-R and preferably Flt and/or KDR can be obtained. Such compounds are preferably used to treat patients suffering from cell proliferative disorders characterized by inappropriate PDGF-R activity.
摘要翻译：本发明涉及可以抑制血小板衍生生长因子受体（PDGF-R）活性的化合物，优选地，这些化合物也抑制PDGF-R超家族的其他成员的活性，并且对PDGF-R超家族的成员是选择性的。 PDGF-R超家族包括PDGF-R和PDGF-R相关的激酶Flt和KDR。特征化合物在细胞培养物中是有活性的，以降低PDGF-R，优选一种或多种PDGF-R相关激酶的活性。以下描述特征化合物A10（参见图1a）及其抑制体内肿瘤细胞生长的能力的实例。使用本申请作为指导，可以获得能够抑制PDGF-R，优选Flt和/或KDR的其它化合物。这些化合物优选用于治疗患有以不适当的PDGF-R活性为特征的细胞增殖性疾病的患者。

5. 发明申请

US20050171176A1 Pharmaceutically active aromatic guanylhydrazones 审中-公开
标题翻译：药用活性芳香脒腙
公开(公告)号：US20050171176A1
公开(公告)日：2005-08-04
申请号：US11052325
申请日：2005-02-07
申请人： Dorian Bevec , Joachim Hauber , Sabine Obert , Gyorgy Keri , Laszlo Orfi , Istvan Szekely , Axel Choidas , Gerald Bacher
发明人： Dorian Bevec , Joachim Hauber , Sabine Obert , Gyorgy Keri , Laszlo Orfi , Istvan Szekely , Axel Choidas , Gerald Bacher
IPC分类号： A61K31/155 , A61K31/17 , A61K31/22 , A61K31/4164 , A61K45/06 , A61P31/04 , A61P31/18 , C07C281/18 , A61K31/4172 , A61K31/165
CPC分类号： A61K45/06 , A61K31/155 , A61K31/17 , A61K31/4164 , C07C281/18 , Y02A50/402 , Y02A50/47 , Y02A50/471 , Y02A50/473 , Y02A50/475 , Y02A50/479 , Y02A50/481
摘要： The present invention relates to aromatic guanylhydrazone compounds and their use as pharmaceutically active agents, especially for prophylaxis and treatment of virally caused diseases and infections, including opportunistic infections. The inventive guanylhydrazone compounds are also useful as inhibitors of deoxyhypusine synthase and as inhibitors for nuclear export in infectious diseases and may be used to regulate bacterially induced TNF-α production. Furthermore, the aromatic guanylhydrazones exhibit antibacterial activity against Gram positive and Gram negative bacteria and can be regarded as a novel class of antibiotics. In addition, methods for prophylaxis and treatment of virally or bacterially induced infections and diseases are disclosed together with pharmaceutical compositions useful within said methods containing at least one aromatic guanylhydrazone of the present invention as active ingredient.
摘要翻译：本发明涉及芳香脒腙化合物及其作为药物活性剂的用途，特别是用于预防和治疗病毒引起的疾病和感染，包括机会性感染。本发明的脒腙化合物也可用作脱氧酪氨酸合成酶的抑制剂，并且可用作感染性疾病中核出口的抑制剂，并可用于调节细菌诱导的TNF-α产生。此外，芳香脒腙对革兰氏阳性和革兰氏阴性细菌具有抗菌活性，可被认为是一类新型抗生素。此外，还公开了用于预防和治疗病毒或细菌诱导的感染和疾病的方法以及在含有本发明的至少一种芳香脒腙作为活性成分的所述方法中有用的药物组合物。

6. 发明申请

US20070275962A1 Heterobicyclic Compounds as Pharmaceutically Active Agents 审中-公开
标题翻译：异双环化合物作为药物活性剂
公开(公告)号：US20070275962A1
公开(公告)日：2007-11-29
申请号：US10597120
申请日：2004-09-10
申请人： Anil Koul , Bert Klebl , Gerhard Muller , Andrea Missio , Wilfried Schwab , Doris Hafenbradl , Lars Neumann , Marc-Nicola Sommer , Stefan Muller , Edmund Hoppe , Achim Freisleben , Alexander Backes , Christian Hartung , Beatrice Felber , Birgit Zech , Ola Engkvist , Gyorgy Keri , Laszlo Orfi , Peter Banhegyi , Zoltan Greff , Zoltan Horvath , Zoltan Varga , Peter Marko , Janos Pato , Istvan Szabadkai , Zsolt Szekelyhid , Frigyes Waczek
发明人： Anil Koul , Bert Klebl , Gerhard Muller , Andrea Missio , Wilfried Schwab , Doris Hafenbradl , Lars Neumann , Marc-Nicola Sommer , Stefan Muller , Edmund Hoppe , Achim Freisleben , Alexander Backes , Christian Hartung , Beatrice Felber , Birgit Zech , Ola Engkvist , Gyorgy Keri , Laszlo Orfi , Peter Banhegyi , Zoltan Greff , Zoltan Horvath , Zoltan Varga , Peter Marko , Janos Pato , Istvan Szabadkai , Zsolt Szekelyhid , Frigyes Waczek
IPC分类号： C07D495/04 , A61P31/04 , C07D209/42 , C07D333/66 , C07D333/68 , C07D495/10 , C07D409/12 , C07D413/14 , C07D491/04 , C07D493/04
CPC分类号： C07D409/12 , C07D209/42 , C07D333/66 , C07D333/68 , C07D491/04 , C07D493/04 , C07D495/04 , C07D495/10
摘要： Described are heterobicyclic compounds such as 4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylic acid amides, 4,7-dihydro-5H-thieno[2,3-c]thiopyran 3-carboxylic acid amides, 4,7-dihydro-5H-thieno[2,3-c]pyran-3-carboxylic acid amides, or benzo[b]thiophene-3-carboxylic acid amides and pharmaceutically acceptable salts thereof, the use of these derivatives for the prophylaxis and/or treatment of various diseases such as infectious diseases, including mycobacteriainduced infections and opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke, as well as compositions containing at least one heterobicyclic compound and/or pharmaceutically acceptable salts thereof. Furthermore, reaction procedures for the synthesis of the heterobicyclic compound are disclosed.
摘要翻译：描述的是杂双环化合物，例如4,5,6,7-四氢苯并[b]噻吩-3-羧酸酰胺，4,7-二氢-5H-噻吩并[2,3-c]噻喃-3-羧酸酰胺，4 ，7-二氢-5H-噻吩并[2,3-c]吡喃-3-羧酸酰胺或苯并[b]噻吩-3-羧酸酰胺及其药学上可接受的盐，这些衍生物用于预防和 /或治疗诸如感染性疾病，包括分泌细菌感染和机会性疾病，朊病毒疾病，免疫疾病，自身免疫疾病，双相和临床病症，心血管疾病，细胞增殖性疾病，糖尿病，炎症，移植排斥，勃起功能障碍，神经变性疾病和中风，以及含有至少一种杂双环化合物和/或其药学上可接受的盐的组合物。此外，公开了用于合成杂双环化合物的反应程序。

7. 发明申请

US20090018149A1 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives and methods for medical intervention against mycobacterial infections 审中-公开
标题翻译： 4,5,6,7-四氢苯并[b]噻吩衍生物和用于针对分枝杆菌感染的医疗干预的方法
公开(公告)号：US20090018149A1
公开(公告)日：2009-01-15
申请号：US10510791
申请日：2003-04-09
申请人： Andrea Missio , Gerald Bacher , Anil Koul , Axel Choidas , Peter Banhegyi , Zoltan Greff , Gyorgy Keri , Peter Marko , Laszlo Orfi , Janos Pato , Frigyes Waczek
发明人： Andrea Missio , Gerald Bacher , Anil Koul , Axel Choidas , Peter Banhegyi , Zoltan Greff , Gyorgy Keri , Peter Marko , Laszlo Orfi , Janos Pato , Frigyes Waczek
IPC分类号： A61K31/381 , A61P31/04 , A61P31/12 , C07D333/52 , C07D409/02 , G01N33/53 , A61K31/4178 , C07D495/02 , A61K31/519 , A61K31/4535
CPC分类号： C07D409/12 , C07D333/66 , C07D333/68 , C07D409/14 , C07D495/04 , C07D495/14
摘要： Described are 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives and pharmaceutically acceptable salts thereof, the use of these derivatives for the prophylaxis and/or treatment of mycobacteria-induced infections and opportunistic infections, as well as compositions containing at least one 4,5,6,7-tetrahydrobenzo[b]thiophene derivative and/or pharmaceutically acceptable salts thereof. Furthermore, the present application refers to the use of mycobacterial protein serine/threonine kinases for developing methods for detection and determination of these kinases for recognising and monitoring diseases and for controlling therapy of diseases.
摘要翻译：描述了4,5,6,7-四氢苯并[b]噻吩衍生物及其药学上可接受的盐，这些衍生物用于预防和/或治疗分枝杆菌诱导的感染和机会性感染，以及至少含有一种4,5,6,7-四氢苯并[b]噻吩衍生物和/或其药学上可接受的盐。此外，本申请是指使用分枝杆菌蛋白丝氨酸/苏氨酸激酶来开发用于检测和测定这些用于识别和监测疾病和控制疾病治疗的这些激酶的方法。

8. 发明申请

US20080207677A1 Napthyridine Compounds As Rock Inhibitors 审中-公开
标题翻译：萘啶化合物作为岩石抑制剂
公开(公告)号：US20080207677A1
公开(公告)日：2008-08-28
申请号：US11813236
申请日：2006-01-02
申请人： Stefan Muller , Wilfried Schwab , Bert Klebl , Doris Hafenbradl , Edmund Hoppe , Zoltan Horvath , Gyorgy Keri , Zoltan Varga , Laszlo Orfi , Jeno Marosfalvi , Gerhard Muller
发明人： Stefan Muller , Wilfried Schwab , Bert Klebl , Doris Hafenbradl , Edmund Hoppe , Zoltan Horvath , Gyorgy Keri , Zoltan Varga , Laszlo Orfi , Jeno Marosfalvi , Gerhard Muller
IPC分类号： A61K31/4375 , C07D471/04 , A61P35/00
CPC分类号： C07D471/04
摘要： The present invention relates to compounds having a naphthyridine scaffold, and stereoisomeric forms, prodrugs, solvates, hydrates and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these naphthyridine derivatives together with pharmaceutically acceptable carrier, excipient and/or diluents. Said naphthyridine compounds have been identified as inhibitors of the protein kinase ROCK2, also known as Rho-kinase, and are useful for the treatment of cancers (tumor growth and metastases), erectile dysfunction, cardiovascular diseases, hypertension, angina pectoris, cerebral ischaemia, cerebral vasospasm, myocardial ischaemia, coronary vasospasm, heart failure, myocardial hypertrophy, atherosclerosis, restenosis, spinal cord injuries, neuronal degeneration, thrombotic disorders, asthma, glaucoma, inflammation, anti-viral diseases (e.g. HIV), and osteoporosis.
摘要翻译：本发明涉及具有萘啶支架的化合物，以及这些化合物的立体异构形式，前体药物，溶剂合物，水合物和/或药学上可接受的盐，以及含有这些萘啶衍生物中至少一种以及药学上可接受的载体，赋形剂和 /或稀释剂。所述萘啶化合物已被鉴定为蛋白激酶ROCK2（也称为Rho-激酶）的抑制剂，可用于治疗癌症（肿瘤生长和转移），勃起功能障碍，心血管疾病，高血压，心绞痛，脑缺血，脑血管痉挛，心肌缺血，冠状动脉血管痉挛，心力衰竭，心肌肥大，动脉粥样硬化，再狭窄，脊髓损伤，神经元变性，血栓形成障碍，哮喘，青光眼，炎症，抗病毒疾病（例如HIV）和骨质疏松症。

9. 发明申请

US20080214583A1 7H-Pyrrolo[2,3-D]Pyrimidine Derivatives, As Well As Their Therapeutically Acceptable Salts, Pharmaceutical Preparations Containing Them And Process For Production The Active Agent 审中-公开
标题翻译： 7H-吡咯并[2,3-D]嘧啶衍生物及其治疗上可接受的盐，含有它们的药物制剂及其制备方法活性剂
公开(公告)号：US20080214583A1
公开(公告)日：2008-09-04
申请号：US11587851
申请日：2005-04-25
申请人： Janos Szolcsanyi , Laszlo Orfi , Gyorgy Keri , Frigyes Waczek , Erika Pinter , Zsusanna Helyes , Tamas Szuts , Jozsef Nemeth
发明人： Janos Szolcsanyi , Laszlo Orfi , Gyorgy Keri , Frigyes Waczek , Erika Pinter , Zsusanna Helyes , Tamas Szuts , Jozsef Nemeth
IPC分类号： A61K31/519 , C07D487/04 , A61P19/08 , A61P19/02 , A61P25/00 , A61P29/00
CPC分类号： C07D487/04
摘要： The invention relates to new 7H-pyrrolo[2,3-d]pyrimidine derivatives, as well as their therapeutically acceptable salts, pharmaceutical preparations containing them and process for producing the active agent. The pharmaceutical preparation is adventageously antiphlogistic and analgetic one, a preparation reducing neuropathic hyperalgesia and rheumatic arthritis, a preparation for hindering destruction of bones chondrus, being applicable for treatment of other diseases, which may be connected with other inflammatory processes e.g. asthma, eczema or psoriasis.
摘要翻译：本发明涉及新的7H-吡咯并[2,3-d]嘧啶衍生物及其治疗上可接受的盐，含有它们的药物制剂和生产活性剂的方法。药物制剂是抗炎和止痛药物，减轻神经性痛觉过敏和风湿性关节炎的制剂，用于阻止骨骼软骨破坏的制剂，可用于治疗其它疾病，其可与其它炎症过程相关，例如与其它炎症过程相关。哮喘，湿疹或牛皮癣。

10. 发明申请

US20060105445A1 Medium and method for enriching, purifying or depleting atp binding proteins from a pool of proteins 审中-公开
标题翻译：用于从蛋白质池中富集，纯化或消耗atp结合蛋白的培养基和方法
公开(公告)号：US20060105445A1
公开(公告)日：2006-05-18
申请号：US10523577
申请日：2003-07-29
申请人： Klaus Godl , Andrea Missio , Henrik Daub , Matthias Stein-Gerlach , Zoltan Greff , Gyorgy Keri , Laszlo Orfi , Zoltan Varga , Bert Klebl
发明人： Klaus Godl , Andrea Missio , Henrik Daub , Matthias Stein-Gerlach , Zoltan Greff , Gyorgy Keri , Laszlo Orfi , Zoltan Varga , Bert Klebl
IPC分类号： C12N9/12 , C07K14/705
CPC分类号： G01N33/573 , A61K38/00 , C07D401/04 , C07D401/14 , C07K1/22 , G01N33/6803 , G01N2333/91205
摘要： The present invention relates to a medium and a method for enriching ATP binding proteins, e.g. proteinkinases, from a pool of proteins, like a proteome. The medium of the present invention comprises specific inhibitors, e.g. at least one of the compounds 4-[4-(4-fluoro-phenyl)-5-pyridine-4-yl-1H-imidazole-2-yl]-benzylamine, 2-[4-(2-Amino-ethoxy)-phenylamino]-6-(2,6-dichloro-phenyl)-8-methyl-8H-pyrido[2,3-d]pyrimidine-7-one, 2-[1-(3-aminopropyl)-1H-indole-3-yl)maleinmide, 3-[1-(3-Aminopropyl)-1H-indol-3-yl]-3-(1H-indol 3-yl)-maleinmide, 3-[1-(3-Aminopropyl)-1H-indol-3-yl]4-(1-methyl-1H-indol-3-yl) maleinimide, 3-(8-Aminomethyl-6,7,8,9-tetrahydropyrido-[1,2-a]-indol-10-yl) (1-methyl-1H-indol -3-yl)-maleinmide, [6-(3-Amino-propoxy)-methoxy-quinazolin-4-yl]-(3-chloro-phenyl)-amine, 6-(3-Amino-propoxy)-7-methoxy-quinazolin-4-yl-(3-chloro-4-fluoro-phenyl)-amine, 6-(3Amino-propoxy)-7-methoxy-quinazolin-4-yl]-(3-bromo-phenyl)-amine and 4-[4-(4-Amino-butyl)-piperazin-1-yl-methyl]-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide immobilized on a support material. According to the method of the present invention the above-mentioned immobilized compounds are used to selectively bind protein kinases from a pool of heterogeneous proteins.
摘要翻译：本发明涉及一种培养基和一种富含ATP结合蛋白的方法，蛋白质蛋白酶，来自蛋白质库，如蛋白质组。本发明的培养基包含特异性抑制剂，例如，至少一种化合物4- [4-（4-氟 - 苯基）-5-吡啶-4-基-1H-咪唑-2-基] - 苄胺，2- [4-（2-氨基 - 乙氧基） - 苯基氨基] -6-（2,6-二氯 - 苯基）-8-甲基-8H-吡啶并[2,3-d]嘧啶-7-酮，2- [1-（3-氨基丙基）-1H-吲哚 -3-（3-氨基丙基）-1H-吲哚-3-基] -3-（1H-吲哚-3-基） - 马来酰亚胺，3- [1-（3-氨基丙基） -1H-吲哚-3-基] 4-（1-甲基-1H-吲哚-3-基）马来酰亚胺，3-（8-氨基甲基-6,7,8,9-四氢吡啶并[1,2-a] - 吲哚-10-基）（1-甲基-1H-吲哚-3-基） - 马来酰亚胺，[6-（3-氨基 - 丙氧基） - 甲氧基 - 喹唑啉-4-基] - （3-氯 - 苯基） - 胺，6-（3-氨基 - 丙氧基）-7-甲氧基 - 喹唑啉-4-基 - （3-氯-4-氟 - 苯基） - 胺，6-（3Amin-丙氧基）-7-甲氧基 - 喹唑啉 -4-基] - （3-溴 - 苯基） - 胺和4- [4-（4-氨基 - 丁基） - 哌嗪-1-基 - 甲基] -N- [4-甲基-3-（4- 吡啶-3-基 - 嘧啶-2-基氨基） - 苯基] - 苯甲酰胺固定在载体材料上。根据本发明的方法，上述固定化化合物用于选择性地结合来自异质蛋白库的蛋白激酶。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式